A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis.

Trial Profile

A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Fulranumab (Primary) ; Oxycodone
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2016 Primary endpoint has been met. (Pain intensity), as per an article published in the International Journal of Clinical Practice.
    • 01 Jun 2016 Results published in the International Journal of Clinical Practice
    • 11 May 2013 Results presented at the 32nd Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top